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The Jeryl Lynn strain of mumps vaccine live (MVL) was developed in 1966 by Merck Co. and has been widely used in the
U.S. and other countries since the early 1970s. Partial sequencing has recently shown that the vaccine contains a mixture
of two substrains with substantially different nucleotide sequences. We have determined the complete genomic sequences
of both substrains and identified 414 nucleotide differences (2.69%), leading to 87 amino acid substitutions (1.67%). We used
this information to develop methods for quantification of the substrain components in vaccine samples based on PCR and
restriction enzyme cleavage and oligonucleotide microarray hybridization and monitored their dynamics in viral populations
propagated in different conditions. Passaging Jeryl Lynn strain in Vero or CEF cell cultures resulted in rapid selection of the
major component JL1, while growth in embryonated chicken eggs (ECE) favored accumulation of the minor component JL2.
Based on the findings presented here, it is proposed that the substrain composition of Jeryl Lynn vaccine can be monitored
as a part of its quality control to ensure consistency of the vaccine. © 2002 Elsevier Science (USA)INTRODUCTION
Jeryl Lynn strain of mumps virus was the first among
many attenuated strains that was used for production of
mumps vaccine live (MVL) (Hilleman, 1966; Young et al.,
1967). It was the basis for MVL produced in cultures of
chicken embryo cells by Merck and used in the U.S. and
other countries for mass vaccinations. Unlike some other
strains that have a mixed record of success, Jeryl Lynn
has been proven to be safe and efficacious and was
instrumental in control of mumps infections in many
countries. The Jeryl Lynn strain has been previously
shown to contain a mixture of two distinct viral sub-
strains, termed JL1 and JL2 (Afzal et al., 1992, 1993).
Analysis of cDNA clones showed that there was a 4:1
ratio between JL1 and JL2 in production bulks of Merck
MVL. Partial sequences of the HN and SH genes from
both substrains were published and it was suggested
that the substrains differ substantially, but the magnitude
of the overall sequence divergence was unknown. There
is no information about potential differences in the bio-
logical properties of the substrains; however, preliminary
serological studies suggest that the heterogeneity of
Merck MVL provides for the induction of a broadly reac-
1 To whom correspondence and reprint requests should be ad-171tive immune response that may be partly responsible for
the vaccine’s high efficacy (Afzal et al., 1992). If the
growth characteristics of substrains differ, variation in
production conditions could result in a changed ratio of
the major (JL1) and the minor (JL2) substrains, which in
turn may affect safety and/or efficacy of the vaccine. To
ensure consistency of vaccine production, it was desir-
able to develop a rapid quantitative method for measur-
ing the relative contents of both substrains. Such a con-
sistency monitoring method would be especially benefi-
cial if major changes in production are implemented,
such as the use of another seed virus preparation or cell
substrate. In this article we report complete nucleotide
sequences of both substrains and the determination of
the relative JL1:JL2 ratio by using the mutant analysis by
PCR and restriction enzyme cleavage (MAPREC) assay
in various Jeryl Lynn preparations, including experimen-
tal batches of MVL produced in ECE. Based on the
results reported here, we propose that MAPREC assay
can serve as a monitoring consistency tool for examining
vaccine production.
RESULTS
Plaque-screening for JL1 and JL2 sub-strains
The observation that Jeryl Lynn strain is a mixture ofKey Words: genetic stability; quasispecies; viral vacc
hybridization.
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two distinct substrains (Afzal et al., 1993) was based on
partial sequencing of the SH and HN genes. We at-
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tempted to isolate the individual substrains by direct
plaque-purification on Vero and CEF cells after infection
with unpassaged bulks of Merck MVL and Jeryl Lynn
strain passaged in ECE. Forty-seven plaques were iso-
lated from Vero cells infected with Merck vaccine bulk
and 47 plaques were isolated from Vero cells infected
with MVL passaged in ECE. To screen for the individual
substrains, viral RNA was extracted and reverse tran-
scribed, and the entire coding region of the SH gene was
PCR-amplified and sequenced. The published SH se-
quences of the JL1 and JL2 substrains served as refer-
ences and allowed us to identify the genotype of each
plaque. Surprisingly, all 94 analyzed plaques were of JL1
genotype. Notably, the SH sequences from some
plaques contained differences from the published SH
gene sequences (Genbank Accession Nos. X63707 and
D90232), most likely reflecting the quasispecies nature
of RNA viruses. Interestingly, no plaques were generated
in the infected CEF cultures.
Determination of complete consensus sequences for
JL1 and JL2
The sequencing strategy involved PCR amplification of
20 overlapping 1-kb DNA fragments. PCR products were
then sequenced using ABI 310 genetic analyzer with a
set of sense and antisense primers spaced 300–500
nucleotides from each other. The resulting overlapping
readable sequences of both complementary strands
were assembled into a single contig, in which all regions
were determined with a two- to fivefold redundancy. The
sequence of a previously plaque-purified JL1 clone
grown in Vero cells served as a reference sequence to
deduce the unknown JL2 sequence present in unpas-
saged batch of Merck MVL and MVL passaged in ECE
(JLP003). Complete genome sequencing of an unpas-
saged bulk of Merck MVL and of an experimental MVL
vaccine passaged in ECE (JLP003) revealed multiple
ambiguous sites at which two bases were present, re-
flecting the presence of JL1 and JL2 sequences. It was
reasonable to assume that the nucleotide different from
the plaque-derived JL1 reference sequence belonged to
the unknown JL2 consensus sequence. Since our at-
tempts to plaque-purify the JL2 substrain failed, we used
these sequence data to deduce the tentative sequence
of the JL2 strain.
Verification of the tentative JL2 sequence
The tentative JL2 sequence was used to synthesize
primers for the selective PCR amplification and direct
sequencing of the JL2 cDNA. All PCR primers contained
two or more JL2-specific nucleotides at their 3 end to
prevent them from binding to and to prevent amplification
of JL1 substrain sequences. The JL2-specific primers
were then used to PCR amplify cDNA from the same two
MVL samples that were used to deduce the tentative JL2
sequence. Sequencing of the PCR fragments amplified
with JL2 specific primers produced clear and unambig-
uous results, which were identical to the tentative JL2
sequence. The sequence information obtained through
direct cDNA amplification has a significant advantage,
because it represents the real JL2 consensus sequence,
rather than a sequence of a single clone randomly
picked from the viral quasispecies. Individual cDNA
clones can contain point mutations, as seen in the JL1
and JL2 SH screening experiments, and thus to deter-
mine the real consensus sequence of a viral genome,
multiple independent clones must be sequenced.
JL1/JL2 differences at nucleotide and amino acid
level
Results of the comparison between JL1 and JL2 se-
quences are presented in Table 1. There were a total of
414 nucleotide differences (2.69%), of which 403 were in
protein-coding regions and 11 were in noncoding areas.
The nucleotide differences resulted in 87 amino acid
substitutions (1.67%) in a total of 5151 amino acids, the
complete coding capacity of mumps virus RNA. These
amino acid differences were unevenly distributed among
individual viral genes, with the L protein being the most
TABLE 1
Nucleotide and Amino Acid Differences between JL1 and JL2 Components of Jeryl Lynn Strain
Gene
Nucleotides,
total
Nucleotide
differences % Nucl
Amino acids,
total
Amino acid
differences % aa
Missense to
silent ratio
NP 1650 38 2.3 549 7 0.24 0.23
P 1176 37 3.14 391 12 3.06 0.48
V 675 19 2.81 225 8 3.55 0.73
I 516 22 4.26 171 7 4.09 0.47
M 1128 22 1.95 375 5 1.33 0.29
F 1617 46 2.84 538 13 2.41 0.39
SH 174 12 6.89 59 8 13.55 2.00
HN 1749 50 2.86 582 14 2.4 0.39
L 6786 157 2.3 2261 13 0.57 0.09
172 AMEXIS ET AL.
conserved (99.4%), and the SH protein being most vari-
able (87%) at the amino acid level (Fig. 1). The ratio of
missense to silent mutations ranged from 0.09 (L protein)
to 2.0 (SH protein), suggesting that the structures of the
proteins are under widely different structural and func-
tional constraints. This is consistent with L protein being
an intracellular protein playing the major role in the viral
RNA replication and being under no evolutionary pres-
sure from the host immune system, while the physiolog-
ical role of the SH protein, if any, remains unknown.
SH gene screening from passaged MVL in Vero and
CEF cells
Since JL2 failed to produce plaques in both cell sys-
tems, plaque analysis could not be used to quantify
relative contents of both strains grown in different cell
substrates. Therefore we used the TA-cloning system
(Clontech) and PCR-amplified the highly variable SH
gene to quantify the JL1 and JL2 substrains. We analyzed
the JL1:JL2 ratio in Merck MVL vaccine that was serially
passaged in Vero and CEF cells. A total of 27 individual
bacterial clones each for Vero passage levels 1 and 4
were picked and the SH coding region was sequenced.
None of the 54 Vero clones were JL2 specific, indicating
a significant reduction of the JL2 substrain upon growth
in Vero cells. A total of 64 bacterial clones were picked
from the CEF-passaged samples. Of 32 cDNA clones
examined from passage level one, 27 were of JL1 geno-
type, and five were of JL2 genotype (15.6%). CEF passage
level 4 contained only two JL2 isolates of 32 sequenced
TA clones (6.25%), indicating that both Vero and CEF
cells appear to select against the JL2 substrain in Merck
MVL.
MAPREC quantification of JL1 and JL2 substrains in
passaged viral stocks
After the results of the TA cloning indicated a signifi-
cant change in the JL1-to-JL2 ratio, we decided to de-
velop a more sensitive and accurate quantification for
both substrains in samples and designed MAPREC as-
says to test for several nucleotides distinguishing JL1
from JL2 (877-A/G, 11293-T/C, and 12997-C/T). The tests
were used to quantify the absolute contents of JL1 and
JL2 in the same serially passaged MVL samples that
were used in the TA-cloning experiments. The MAPREC
data confirmed the results from the TA-cloning experi-
ments, that by the first passage of Merck MVL on Vero
cells, the percentage of JL2 decreased from 20 to 2% and
none could be detected in subsequent passages (not
shown). Similarly, serial passaging of the virus in CEF
cells resulted in a decrease of the JL2 content to 13.4% in
the first passage to 6.8% by the fourth passage.
Contents of JL1 and JL2 substrains in embryonated
chicken eggs (ECE)-passaged Jeryl Lynn stocks
ECE were previously used for production of MVL made
from other attenuated strains of mumps virus, so it was
interesting to see how growth of the Jeryl Lynn strain in
this substrate would affect the JL1-to-JL2 ratio. MVL
batch produced by Merck was consecutively passaged
three times in ECE, with each step being repeated at
least twice to obtain parallel lineages. We used MAPREC
to determine the quantity of C (JL1 genotype) and T (JL2
genotype) at nucleotide 12,997 in nine virus stocks inde-
pendently prepared in ECE, which included the two
master-seeds (JLSP001–JLSP002), three working-seeds
(JLST004–JLST006), and four production lots (JLP002–
JLP005) (Fig. 2). The results demonstrated that unlike
CEF and Vero cells, passaging of Jeryl Lynn strain in ECE
resulted in the rapid accumulation of JL2 (over 90%) and
loss of JL1, suggesting that JL2 has a strong selection
advantage in ECE.
Batch-to-batch variability of JL1-to-JL2 ratio in ECE-
passaged virus stocks
The results presented in Fig. 2 revealed some variabil-
ity of JL1 and JL2 contents in the four experimental lots
(JLP002–JLP005). To confirm that this reflects a system-
FIG. 1. Comparison of amino acid differences between the JL1 and
JL2 substrains in all individual viral genes. Virus samples from Merck
(MVL) and Aventis-Pasteur (JLP003) were used to generate the JL1 and
JL2 consensus sequences.
173SEQUENCE DIVERSITY OF JERYL LYNN STRAIN OF MUMPS VIRUS
atic difference, the four production lots were analyzed by
MAPREC at two additional substrain specific sites: 877
(NP gene) and 11,293 (L gene) (Fig. 3 and Table 2). The
results confirmed that the four production lots (JLP002–
JLP005) differed from each other, showing that MAPREC
can detect batch-to-batch genetic variations in the vac-
cine virus.
Discrimination between JL1 and JL2 substrains by
oligonucleotide microarray hybridization
There are other alternative methods for discrimination
of mutants and nucleotide polymorphisms in viral popu-
lations. For instance, we have used MALDI-TOF mass
spectrometry (MassArray Technology, Sequenom Inc.)
for this purpose (Amexis et al., 2001). Recently another
technique based on hybridization with microarrays of
immobilized oligonucleotides (oligonucleotide micro-
chips) was shown to be highly efficient for discrimination
of single-base polymorphisms. We explored utility of this
method for quantitative analysis of the relative contents
of JL1 and JL2 in viral stocks. Figure 4 shows that hy-
bridization with four pairs of substrain-specific oligonu-
cleotides could easily distinguish between a plaque-
purified JL1 clone, MVL (Merck), and ECE-passaged vi-
rus (JLSP; JLST and JLP virus stocks) that resulted in
widely different JL1 and JL2 ratios.
DISCUSSION
Maintaining production consistency is a cornerstone
of vaccine safety and is based on strict adherence to
validated and approved manufacturing protocols, stan-
dard sourcing, use of a seed virus system, and rigorous
testing of bulk materials and the final product. Incase of
live viral vaccines this issue is particularly important for
most RNA viruses due to their inherent genetic instability.
In extreme cases, e.g., for oral poliovirus vaccine, this
instability or propensity to partial reversion to virulence
required that each production lot be tested for safety in
primates (WHO, 1999). A major reason consistency tests
are not performed during the course of routine produc-
tion of many live viral vaccines is that, in most cases, no
efficient and reliable methods with the necessary sensi-
tivity and specificity exists. This prompted investigators
to develop new animal tests for assessing mumps neu-
rovirulence (Rubin et al., 1999, 2000). However, most
animal systems do not fully mimic the human patholog-
ical processes, thereby making it difficult to interpret
results.
Recently we developed a molecular method (MA-
PREC) based on quantitative mutant analysis of neuro-
virulent revertants in batches of OPV. By using MAPREC
to quantify mutations associated with neurovirulence, we
could unambiguously identify all batches of OPV with
unacceptable mutation levels. The MAPREC method was
recommended by WHO as an in vitro test of choice for lot
release of type 3 OPV. We also developed MAPREC
assays for two other types of OPV which can be used for
consistency monitoring of vaccine production, even
though the mutations in type 1 and type 2 OPV do not
produce such a dramatic impact on virus neurovirulence.
This led us to propose a broader approach that we call
“molecular consistency monitoring” (MCM) of live viral
vaccines. This new approach relies on the generation of
a mutational profile that is generated by whole genome
sequencing from a viral live vaccine with a proven safety
record. This molecular profile allows for the monitoring of
product consistency during manufacturing without deter-
mining the biological function, if any, of new mutations
that can accumulate during vaccine production.
Our experience with OPV showed feasibility of molec-
ular monitoring for consistency of vaccine production.
Thus we decided to expand this approach and to apply it
to other live viral vaccines. Some strains used in vac-
cines against mumps (e.g., Jeryl Lynn) are highly safe
and efficacious, while others (Leningrad 3 and Urabe
AM9) are genetically unstable (Brown et al., 1991; Lev-
enbuk et al., 1979; McDonald et al., 1989; Sugiura and
Yamada, 1991), or insufficiently immunogenic (Rubini)
(Chamot et al., 1998; Toscani et al., 1996). Recently we
performed a study on Urabe vaccines produced by two
manufacturers (Amexis et al., 2001a). One of the products
showed an excessive rate of adverse reactions and was
withdrawn, while the other is still being produced and
used with no excessive adverse events in vaccinees. Our
results showed that two products can be distinguished
FIG. 2. MAPREC screening of MVL samples passaged in ECE.
Relative quantities of JL1 and JL2 were determined by measuring the
contents of 12997-C and 12997-T. MVL (Merck) was used to determine
the JL1:JL2 ratio in unpassaged material. JLSP bulks represent passage
level 1 (master-seed), JLST4-6 represent passage level 2 (working-
seed), and JLP2-5 are experimental production bulks.
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by their mutational profiles and that this profile could be
used for monitoring consistency (Amexis et al., 2001a).
After over two decades of large-scale usage of mumps
vaccine prepared from Jeryl Lynn strain, reports of seri-
ous adverse reactions caused by Jeryl Lynn are ex-
tremely rare and a causal relationship has never been
proven (Ehrengut and Zastrow, 1989; Miller et al., 1993;
Young et al., 1967). Recently some manufacturers con-
sidered producing vaccine from Merck’s Jeryl Lynn strain
or its derivatives. This development deserves special
attention since any change in production protocol can
result in a change of vaccine properties, including its
safety. Since there is no reliable and validated laboratory
test for mumps vaccine safety (Minor, 1997; Rubin et al.,
FIG. 3.MAPREC Analysis at three different nucleotides demonstrating variation of JL1 and JL2 subcomponents in production bulks of mumps virus.
Each MAPREC quantification included a negative control (uncut) and a restriction enzyme digest that discriminates between JL1 and JL2 specific
nucleotides at the position of interest. Two lanes, one with enzyme-digested DNA (D) and the other with undigested control (C), are analyzed for each
sample.
TABLE 2
Consistency of JL1 and JL2 Contents in Batches of Mumps Vaccine
Nucleotide JL1 JL2
JLP002 JLP003 JLP004 JLP005
% JL1 % JL2 % JL1 % JL2 % JL1 % JL2 % JL1 % JL2
877 A Hinf1 G Nla4 13.7 83.2 3.4 91.1 26.0 74.1 18.3 74.4
11,293 T Fnu4H1 C Hinf1 13.7 79.3 5.6 91.6 18.7 70.8 20.7 74.1
12,997 C Hinf1 T EcoR1 16.8 83.3 5.1 92.5 18.7 74.8 17.9 78.2
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1999), we initiated the study described in this article to
develop alternative surrogate markers suitable for con-
sistency monitoring of MVL produced from the Jeryl Lynn
strain and its derivatives.
One of the important results of this work is the deter-
mination of the complete nucleotide sequences for both
substrains of the Jeryl Lynn strain. The two substrains
differ at 414 nucleotides, leading to 87 amino acid sub-
stitutions. It is difficult to predict any particular biological
manifestations of these differences, since the molecular
structures of mumps virus proteins, and in many cases
their functions, are not well characterized. It is clear,
however, that at least some of the differences between
the substrains are not neutral since, as has been shown
in this article, JL1 and JL2 exhibit differences in in vitro
growth characteristics in different cell substrates. The
knowledge of full-length sequences of JL1 and JL2 can
be used to examine the biological characteristics and
differences of both substrains in a reverse genetics sys-
tem. Study of the in vitro and in vivo effects of site-
directed mutations can help mapping the functional do-
mains of the mumps virus genome and identify determi-
nants of virulence and attenuation.
The rapid disappearance of JL2 during virus passag-
ing in Vero and CEF cells, as detected by TA-cloning and
MAPREC, suggests that JL2 replicates poorly in Vero and
CEF cell cultures or may require the presence of JL1 as
a helper. It is also noteworthy that JL1 and JL2 substrains
differ at eight nucleotides at the 3-(genomic RNA), and
six bases at the 5-untranslated regions, usually highly
conserved regions in Paramyxoviridae. Whether these
differences affect the ability of the JL2 substrain to initi-
ate efficient replication cycle in specific cell types, or
other factors impair its replication in cell cultures, re-
mains unknown.
On the other hand JL2 is not a completely defective
FIG. 4. Discrimination and quantitative analysis of JL1 and JL2 substrains (SH gene) by oligonucleotide microarray hybridization. Purified PCR
products from a plaque purified JL1 clone (1), MVL Merck (2), JLSP bulk (3), JLST bulk (4), and JLP production bulk (5) were hybridized to the
oligonucleotide microarray. The left panel shows hybridization patterns determined with a fluorescent scanner (Cy5;Cy3), the right panel presents the
results of quantification with QuantArray software.
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satellite since it is rapidly selected for during growth in
ECE and is maintained in CEF at a lower level. The
relationship between JL1 and JL2 may be a good illus-
tration of a synergistic or cooperative effect between
individual subcomponents of viral quasispecies. JL1 ap-
pears to be better adapted to growth in cell cultures,
while JL2 grows better in chicken embryos. In this re-
spect it would be very interesting to study the primary
targets for replication and the pathology caused in
chicken embryos with pure JL1 and JL2 virus stocks. It
would also be interesting to study the relative immuno-
genicity of these JL1 and JL2 stocks in humans and
laboratory animals, which may lead to a better under-
standing of the factors, determining safety and efficacy of
the Jeryl Lynn vaccine. The postulated helper/satellite
relationship between JL1 and JL2 in cell cultures and in
vivo can be expected to contribute to the effectiveness of
the Jeryl Lynn vaccine, more so than either of the sub-
strains alone. Comparison of biological properties of JL1
and JL2 will be required to determine the optimal genetic
composition of MVL.
Ideally, manufacturing consistency should result in a
stable JL1:JL2 ratio, and quantitative mutant analysis
could help to achieve this goal. Besides MAPREC and
oligonucleotide microarray hybridization described in
this article, other methods suitable for sensitive quanti-
tative genotyping, e.g., based on MALDI-TOF mass spec-
trometry (Amexis et al., 2001b), can also be used for this
purpose. It would be advisable to accumulate retrospec-
tive and prospective information about the extent of vari-
ation in the JL1:JL2 ratio in MVL batches and seed virus
stocks. Any new vaccine production based on a conven-
tional (heterogeneous) Jeryl Lynn strain would likely ben-
efit from MAPREC testing to ensure consistency of the
vaccine. The ability to rapidly determine the substrain
ratio would also be helpful to evaluate results from clin-
ical trials of new vaccine products and might help deter-
mine whether any possible adverse reaction may be
associated with changes in the JL1:JL2 ratio. The ability
to monitor molecular consistency of vaccine production
may help give vaccine manufacturers and regulatory
authorities additional confidence in the safety of this
product and provide a reference point for maintaining
consistent product quality in cases when changes have
to be made in the manufacturing process, including the
certification of new seed virus lots. Together with the
results of OPV study (Chumakov, 1999; Chumakov et al.,
1991), the data described in this article provide additional
support for the application of the molecular consistency
approach in the regulation of live viral vaccines.
MATERIALS AND METHODS
Virus passage in ECE
The Jeryl Lynn MVL (Merck Co., West Point, CA) viral
seed was inoculated into the allantoic cavity of 7-day-old
embryonated chicken eggs (0.1 mL per egg). After inoc-
ulation, eggs were incubated for 6 days at 36°C in 60%
relative humidity and stored at 5°C for 24 h before col-
lecting the allantoic fluid, which was then clarified by
centrifugation and stored at60°C. For serial passages,
the clarified harvest was inoculated to a new set of
embryonated chicken eggs by using the same protocol.
Virus passage in cell cultures
Chicken embryo fibroblast (BioWhittaker, MD) and
Vero (ATCC, passage level 145–150) cell cultures were
infected with mumps virus and incubated in DMEM me-
dium with 2% FBS at 36°C. After the development of
extensive cytopathic effect, the culture medium was col-
lected and used for further passage and for extraction of
viral RNA. Each consecutive passage was done with ca.
1:100 dilution of the previous viral stock.
MVL plaque assay
Vero and CEF cells were grown in six-well plates until
90% confluence. Virus was diluted in minimal essential
medium (MEM) containing 2% fetal bovine serum (FBS);
0.25 mL of virus was added to aspirated cell monolayers
and incubated for 1 h at 37°C with 5% CO2. Viral inocu-
lum was then removed from the wells by aspiration and
1.5 mL of an agar overlay was added. The overlay con-
tained 10 vol 2 MEM without phenol red, 10 vol 1.5%
Agar Nobel Gel (Quality Biologicals, Gaithersburg, MD),
and 1 vol FBS. Plates were incubated for 5 min at room
temperature until the agar solidified and transferred to
the CO2 incubator at 37°C. After 5 days, a second layer
of agar overlay containing 0.03% Neutral Red solution
(Gibco-BRL/Life Technologies, Gaithersburg, MD) was
added and the plates were incubated for additional 4
days after which plaques were counted, or, in the case of
plaque purification, cut out to be used for viral RNA
extraction.
RNA extraction from viral plaques
The inner region of single well-isolated plaques was
picked with a sterile Pasteur pipette and incubated in 20
L H2O for 10 min at 95°C to release the viral RNA. After
this step, the sample was briefly centrifuged and the
supernatant was used for reverse transcriptase reaction
without further purification.
Reverse-transcription of RNA from viral plaques
cDNA was synthesized by using random hexanucle-
otide primers (Rd6) (New England Biolabs, Boston, MA) in
50 L vol with 200 Units Superscript II (Life Technolo-
gies, Gaithersburg, MD). Before addition of the enzyme,
the RT reaction mix was preincubated for 5 min at room
temperature, and reverse transcription was performed
for 45 min at 42°C. After heat inactivation of the enzyme
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for 4 min at 95°C, 2–4 L of the generated cDNA was
used as a template for PCR-amplification with the ACE-
Polymerase Kit (Invitrogen, Carlsbad, CA).
Automated DNA sequencing
DNA sequencing was performed using the Applied
Biosystems Prism 310 Genetic Analyzer with dRhoda-
mine terminators for fluorescent detection. An amount of
150–250 ng of each PCR fragment and 3.2 pmol of a
sequencing primer were used in 20 L reactions to
generate 550–600 bases of overlapping sequence infor-
mation from both strands, which were then aligned by
using Auto Assembler software (Applied Biosystems,
Foster City, CA). The sequences were deposited in Gen-
Bank under Accession Nos. AF338106 for JL1, major
substrain, and AF345290 for JL2, minor substrain.
MAPREC assays
Principle and general MAPREC procedures were de-
scribed previously (Chumakov et al., 1991; Lu et al., 1993).
MAPREC is based on PCR amplification with mutagenic
primer that creates a restriction endonuclease site com-
posed of both primer and template sequences. This site
is toggled by a mutation of interest and can be used for
detection and quantification of it. Briefly, the procedure
involves PCR amplification of single-stranded DNA (pro-
duced by using a 10-fold excess of the sense primer),
which is then radiolabeled by second-strand DNA syn-
thesis with 5-[32P]-antisense primer and Taq DNA poly-
merase. This dsDNA is digested separately with restric-
tion endonucleases specific to both nucleotide variants.
Restriction digests are separated by polyacrylamide gel
electrophoresis, and radioactive DNA bands are quanti-
tated using Storm 860 Phosphoimager (Molecular Dy-
namics). Areas containing both the full-length DNA [Up-
per bands for Samples or Control (US and UC)] and the
restriction fragment [Lower bands for Sample and Con-
trol (LS and LC)] are quantified. The fraction of radioac-
tivity in the restriction fragment compared to total radio-
activity in specific DNA is calculated for each lane: Sam-
ple %  LS/(US  LS); Control %  LC/(UC  LC).
Therefore, net percentage of revertants  Sample % 
Control %. Sequences of primers and of the used restric-
tion enzymes for the MAPREC assays are listed in Table
3. The sum of MAPREC determinations of alternative
nucleotides is not always equal 100% due to incomplete
digestion of PCR-amplified DNA and base misincorpora-
tion during PCR (Lu et al., 1993).
Microarray hybridization
Microarrays of immobilized oligonucleotides (micro-
chips) were prepared by spotting acetic acid solutions of
C6-aminolink-modified oligonucleotides onto silylated
(aldehyde-coated) 1  3 glass slides (Cell Associate,
Inc., TX), followed by reduction with NaBH4 (Chizhikov et
al., 2001). The following oligonucleotides from the SH
gene were used for quantification of JL1: 6449-CCCAAT-
TAGG ACAAGTCC-6466, 6492-CATTCAAATG AAGCTGT-
GCT A-6512, 6300-ATTTCTAGTG CTAATCCTTC-6319,
6446-ATCCCCAATT AGGACAAGTC-6465, and for JL2:
6449-CTCAGTTAGG GCAAGTC-6465, 6492-CATCCAAA-
TG AAGCTGCACT A-6512, 6300-ATTTCTATTG CTAAC-
CCTTC-6319, 6446-ATCCTCAGTT AGGGCAAGTC-6465.
Fluorescent-labeled DNA samples were prepared by
PCR amplification with Cy5-dCTP or Cy3-dCTP. One of
the primers was biotinylated, which allowed strand sep-
aration by using streptavidin-coated GenoPrep magnetic
beads (GenoVision Inc., PA). The single-stranded DNA
was hybridized with oligonucleotide microarrays for 30
min at 45°C, washed, and scanned by using ScanArray
5000 laser scanner (GSI Lumonics, CA) at 570 and 694
nm for Cy3 and Cy5 dyes, respectively.
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